1887
  1. Home
  2. A-Z Publications
  3. Qatar Medical Journal
  4. Volume 2024, Issue 4
  5. Article
Volume 2024, Issue 4
  • ISSN: 0253-8253
  • EISSN: 2227-0426

Abstract

The aim of this study was to investigate the potential cardiac side effects associated with Pfizer/BioNTech and Sinopharm vaccines.

A total of 200 healthy volunteers were enrolled after receiving two doses of Pfizer/BioNTech or Sinopharm vaccine 21 days apart. In addition, 100 healthy, unvaccinated individuals were included as a control group. Cardiac biomarkers such as cardiac troponin-I (cTnI), creatinine kinase–myocardial band (CK-MB), and myoglobin (MYO) were measured 4 days after receiving the second dose of vaccine. In addition, the SARS-CoV-2 neutralizing antibody levels of all participants were also determined.

Post-vaccination findings in both vaccinated groups were comparable. There was no statistically significant difference in cTnI, MYO, and CK-MB levels between the Pfizer/BioNTech and Sinopharm vaccine groups. Furthermore, our results showed that the levels of SARS-CoV-2 neutralizing antibodies stimulated by the Pfizer–BioNTech vaccine were significantly higher (171.19,  < 0.001) compared to the Sinopharm vaccine (70.14). Owing to the successful efficacy of the vaccine and based on the available data, COVID-19 vaccines remain the best option to eliminate the pandemic and its complications.

Our study shows that both Pfizer–BioNTech and Sinopharm vaccines are safe for the heart in the short term, with no significant changes in cardiac biomarkers observed four days after vaccination. The findings suggest that these vaccines are effective and do not pose an immediate risk to cardiovascular health within the observed time frame. However, further research is required to assess the long-term cardiac safety profiles of these vaccines.

© 2024 Dawood, Abed, Khalaf, licensee HBKU Press.
Loading

Article metrics loading...

/content/journals/10.5339/qmj.2024.73
2024-12-30
2025-01-10
Loading full text...

Full text loading...

/deliver/fulltext/qmj/2024/4/qmj.2024.73.html?itemId=/content/journals/10.5339/qmj.2024.73&mimeType=html&fmt=ahah

References

  1. Chang F-Y, Chen H-C, Chen P-J, Ho M-S, Hsieh S-L, Lin J-C, et al. Immunologic aspects of characteristics, diagnosis, and treatment of coronavirus disease 2019 (COVID-19). J Biomed Sci. 2020 Jun4; 27:(1):72. doi: 10.1186/s12929-020-00663-w.
     [Google Scholar]
  2. Adam L, Rosenbaum P, Bonduelle O, Combadière B. Strategies for immunomonitoring after vaccination and during infection. Vaccines (Basel). 2021 Apr9; 9:(4):365. doi: 10.3390/vaccines9040365.
     [Google Scholar]
  3. Vitiello A, Ferrara F. Brief review of the mRNA vaccines COVID-19. Inflammopharmacology. 2021 May1; 29:(3):645–649. doi: 10.1007/s10787-021-00811-0.
     [Google Scholar]
  4. Ke Z, Oton J, Qu K, Cortese M, Zila V, McKeane L, et al. Structures and distributions of SARS-CoV-2 spike proteins on intact virions. Nature. 2020 Dec; 588:(7838):498–502. doi: 10.1038/s41586-020-2665-2.
     [Google Scholar]
  5. Walls AC, Park Y-J, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell. 2020 Apr16; 181:(2):281–292.e6. doi: 10.1016/j.cell.2020.02.058.
     [Google Scholar]
  6. Zhou R, To KK-W, Wong Y-C, Liu L, Zhou B, Li X et al. Acute SARS-CoV-2 infection impairs dendritic cell and T cell responses. Immunity. 2020 Oct13; 53:(4):864–877.e5. doi: 10.1016/j.immuni.2020.07.026.
     [Google Scholar]
  7. Lo Sasso B, Giglio RV, Vidali M, Scazzone C, Bivona G, Gambino CM, et al. Evaluation of anti-SARS-Cov-2 S-RBD IgG antibodies after COVID-19 mRNA BNT162b2 vaccine. Diagnostics (Basel). 2021 Jun22; 11:(7):1135. doi: 10.3390/diagnostics11071135.
     [Google Scholar]
  8. Gambino CM, Lo Sasso B, Colomba C, Giglio RV, Agnello L, Bivona G, et al. Comparison of a rapid immunochromatographic test with a chemiluminescence immunoassay for detection of anti-SARS-CoV-2 IgM and IgG. Biochem Med (Zagreb). 2020 Oct15; 30:(3):030901. doi: 10.11613/BM.2020.030901.
     [Google Scholar]
  9. Fan J, Ma J, Xia N, Sun L, Li B, Liu H. Clinical value of combined detection of CK-MB, MYO, cTnI and plasma NT-proBNP in diagnosis of acute myocardial infarction. Clin Lab. 2017 Mar1; 63:(3):427–433. doi: 10.7754/Clin.Lab.2016.160533.
     [Google Scholar]
  10. Chaichuum S, Tseng C-L, Chang S-C, Chan C-L, Hsu C-Y, Chiang E, et al. Assessment of cardiac adverse events following COVID-19 vaccination by speckle tracking echocardiography. Sci Rep. 2024 May13; 14:(1):10849. doi: 10.1038/s41598-024-61641-y.
     [Google Scholar]
  11. Viskin D, Topilsky Y, Aviram G, Mann T, Sadon S, Hadad Y, et al. Myocarditis associated with COVID-19 vaccination. Circ Cardiovasc Imaging. 2021 Sep;14:(9):e013236. doi: 10.1161/CIRCIMAGING.121.013236.
     [Google Scholar]
  12. Luk A, Clarke B, Dahdah N, Ducharme A, Krahn A, McCrindle B, et al. Myocarditis and pericarditis after COVID-19 mRNA vaccination: Practical considerations for care providers. Can J Cardiol. 2021 Oct; 37:(10):1629–1634. doi: 10.1016/j.cjca.2021.08.001.
     [Google Scholar]
  13. Fazlollahi A, Zahmatyar M, Noori M, Nejadghaderi SA, Sullman MJ, Shekarriz-Foumani R, et al. Cardiac complications following mRNA COVID-19 vaccines: A systematic review of case reports and case series. Rev Med Virol. 2022 Jul; 32:(4):e2318. doi: 10.1002/rmv.2318.
     [Google Scholar]
  14. Yamaura H, Ishikawa H, Otsuka K, Kasayuki N. Reverse takotsubo cardiomyopathy as a cause of acute chest pain in a young woman following COVID-19 vaccination. Circ Cardiovasc Imaging. 2022 Jan; 15:(1):e013661. doi: 10.1161/CIRCIMAGING.121.013661.
     [Google Scholar]
  15. Witberg G, Barda N, Hoss S, Richter I, Wiessman M, Aviv Y, et al. Myocarditis after Covid-19 vaccination in a large health care organization. N Engl J Med. 2021 Dec2; 385:(23):2132–2139. doi: 10.1056/NEJMoa2110737.
     [Google Scholar]
  16. Surveillance o. Myocarditis (Inflammation of the Heart Muscle) Cases Between December 2020 and May 2021 (Including). [Press release] Israeli: Israeli Ministry of Health; [updated 29 June 2023; cited 2021 02 June 2021]. Available from: www.gov.il/en/departments/news/01062021-03.
     [Google Scholar]
  17. Shay DK, Shimabukuro TT, DeStefano F. Myocarditis occurring after immunization with mRNA-based COVID-19 vaccines. JAMA Cardiol. 2021 Oct1; 6:(10):1115–1117. doi: 10.1001/jamacardio.2021.2821.
     [Google Scholar]
  18. Ho JSY, Sia C-H, Ngiam JN, Loh PH, Chew NWS, Kong WK-F, et al. A review of COVID-19 vaccination and the reported cardiac manifestations. Singapore Med J. 2023 Sep; 64:(9):543–549. doi: 10.11622/smedj.2021210.
     [Google Scholar]
  19. Frenck Jr RW, Klein NP, Kitchin N, Gurtman A, Absalon J, Lockhart S, et al. Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents. N Engl J Med. 2021 Jul15; 385:(3):239–250. doi: 10.1056/NEJMoa2107456.
     [Google Scholar]
  20. Kaur RJ, Dutta S, Bhardwaj P, Charan J, Dhingra S, Mitra P, et al. Adverse events reported from COVID-19 vaccine trials: A systematic review. Indian J Clin Biochem. 2021 Oct; 36:(4):427–439. doi: 10.1007/s12291-021-00968-z.
     [Google Scholar]
  21. Edan MH, Khalaf YH, Geeran AM. Pfizer-BioNTech and Sinopharm: A comparative study on biochemical and immunological responses in healthy individuals post-vaccination against COVID-19. J Emerg Med Trauma Acute Care. 2022 Dec 22; 2022:(6):18. doi: 10.5339/jemtac.2022.aimco.18.
     [Google Scholar]
  22. Bodor GS, Porter S, Landt Y, Ladenson JH. Development of monoclonal antibodies for an assay of cardiac troponin-I and preliminary results in suspected cases of myocardial infarction. Clin Chem. 1992 Nov;38:(11):2203–2214. doi: 10.1093/clinchem/38.11.2203.
     [Google Scholar]
  23. Vaidya H, Maynard Y, Dietzler D, Ladenson J. Direct measurement of creatine kinase-MB activity in serum after extraction with a monoclonal antibody specific to the MB isoenzyme. Clin Chem. 1986 Apr; 32:(4):657–663. Available from: https://pubmed.ncbi.nlm.nih.gov/3955814/.
     [Google Scholar]
  24. Silva Jr DP, Landt Y, Porter SE, Ladenson JH. Development and application of monoclonal antibodies to human cardiac myoglobin in a rapid fluorescence immunoassay. Clin Chem. 1991 Aug; 37:(8):1356–1364. doi: 10.1093/clinchem/37.8.1356.
     [Google Scholar]
  25. Li X, Liang C, Xiao X. SARS-CoV-2 neutralizing antibody levels post COVID-19 vaccination based on ELISA method—a small real-world sample exploration. Vaccines (Basel). 2021 Oct6; 9:(10):1139. doi: 10.3390/vaccines9101139.
     [Google Scholar]
  26. Hazebroek M, Everaerts K, Heymans S. Diagnostic approach of myocarditis: Strike the golden mean. Neth Heart J. 2014 Feb; 22:(2):80–84. doi: 10.1007/s12471-013-0499-3.
     [Google Scholar]
  27. Shroff H, Satapathy SK, Crawford JM, Todd NJ, VanWagner LB. Liver injury following SARS-CoV-2 vaccination: A multicenter case series. J Hepatol. 2022 Jan; 76:(1):211–214. doi: 10.1016/j.jhep.2021.07.024.
     [Google Scholar]
  28. Holland DJ, Blazak PL, Martin J, Broom J, Poulter RS, Stanton T. Myocarditis and cardiac complications associated with COVID-19 and mRNA vaccination: A pragmatic narrative review to guide clinical practice. Heart Lung Circ. 2022 Jul; 31:(7):924–933. doi: 10.1016/j.hlc.2022.03.003.
     [Google Scholar]
  29. Das BB, Moskowitz WB, Taylor MB, Palmer A. Myocarditis and pericarditis following mRNA COVID-19 vaccination: What do we know so far? Children (Basel). 2021 Jul 18; 8:(7):607. doi: 10.3390/children8070607.
     [Google Scholar]
  30. Alizadeh LS, Koch V, Yel I, Grünewald LD, Mathies D, Martin S, et al. A case of myocarditis after COVID-19 vaccination: Incidental or consequential? Heliyon. 2022 May 28; 8:(6):e09537. doi: 10.1016/j.heliyon.2022.e09537.
     [Google Scholar]
  31. Sivakumaran P, Sunny J, Tsagkridi A, Khanji MY. Myopericarditis following SARS-CoV-2 mRNA vaccine: The role of cardiac biomarkers and multimodality imaging. Eur Heart J Cardiovasc Imaging. 2022 Feb 22; 23:(3):e134. doi: 10.1093/ehjci/jeab183.
     [Google Scholar]
  32. Imran A, Park W, Sood M. Partially resolving myocardial fibrosis five months following the mRNA COVID-19 vaccine: An MRI based case report. Int J Clin Cardiol. 2022;9:253. doi: 10.23937/2378-2951/1410253.
     [Google Scholar]
  33. Acharya S, Brand M, Lee J, Macqueen D, Arbach A. COVID-19 mRNA vaccine induced troponinemia – is the vaccine a cardiac stressor. Int J Clin Cardiol. 2021, 8:232 doi: 10.23937/2378-2951/1410232.
     [Google Scholar]
  34. Mansanguan S, Charunwatthana P, Piyaphanee W, Dechkhajorn W, Poolcharoen A, Mansanguan C. Cardiovascular manifestation of the BNT162b2 mRNA COVID-19 vaccine in adolescents. Trop Med Infect Dis. 2022 Aug19; 7:(8):196. doi: 10.3390/tropicalmed7080196.
     [Google Scholar]
  35. Al-Hadi HA, Fox KA. Cardiac markers in the early diagnosis and management of patients with acute coronary syndrome. Sultan Qaboos Univ Med J. 2009 Dec; 9:(3):231–246. Available from: https://pubmed.ncbi.nlm.nih.gov/21509305/.
     [Google Scholar]
  36. Normark J, Vikström L, Gwon Y-D, Persson I-L, Edin A, Björsell T, et al. Heterologous ChAdOx1 nCoV-19 and mRNA-1273 vaccination. N Engl J Med. 2021 Sep9; 385:(11):1049–1051. doi: 10.1056/NEJMc2110716.
     [Google Scholar]
  37. Garcia-Beltran WF, Lam EC, Astudillo MG, Yang D, Miller TE, Feldman J, et al. COVID-19-neutralizing antibodies predict disease severity and survival. Cell. 2021; Jan21; 184:(2):476–488.e11. doi: 10.1016/j.cell.2020.12.015.
     [Google Scholar]
/content/journals/10.5339/qmj.2024.73
Loading
Short-term effects of COVID-19 vaccines on cardiac biomarkers: A comparative study between Pfizer/BioNTech and Sinopharm
Qatar Medical Journal 2024, 73 (2024); https://doi.org/10.5339/qmj.2024.73
/content/journals/10.5339/qmj.2024.73
/content/journals/10.5339/qmj.2024.73
Loading

Data & Media loading...

  • Article Type: Research Article
Keyword(s): cardiac biomarkers, COVID-19 vaccines, neutralizing antibodies and side effects

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error